Real-time Estimate Cboe Europe 15:08:17 16/05/2024 BST 5-day change 1st Jan Change
81.16 CHF +0.55% Intraday chart for Alcon Inc. +10.05% +23.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stifel Adjusts Price Target on Alcon to $100 From $95, Maintains Buy Rating MT
Oppenheimer Upgrades Alcon to Outperform From Perform, $103 Price Target MT
Baird Adjusts Price Target on Alcon to $104 From $95, Maintains Outperform Rating MT
Needham Adjusts Price Target on Alcon to $101 From $98, Keeps Buy Rating MT
Global markets live: Apple, Sony, Vodafone, Booking, Walmart... Our Logo
ALCON : Markets rejoice at the Q1 beat; guidance upgraded Alphavalue
Transcript : Alcon Inc., Q1 2024 Earnings Call, May 14, 2024
Alcon: surrounded after its quarterly results CF
Alcon's Swiss Shares Jump After Contact-Lense Sales Boost Earnings DJ
European shares muted ahead of US inflation, Powell remarks; Delivery Hero spikes RE
Alcon Posts Higher Q1 Net Income, Net Sales MT
Alcon Q1 Core Earnings, Sales Rise; 2024 Outlook Reaffirmed MT
Earnings Flash (ALC) ALCON Posts Q1 EPS $0.78 MT
Alcon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
ALCON : Alcon should be viewed with a slightly longer-term lens Alphavalue
Alcon Inc. Approves Gross Dividend CI
Sector Update: Health Care Stocks Edge Higher Late Afternoon MT
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump MT
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump MT
Alcon Announces Management Changes CI
Alcon’s Medical Chief to Retire; Successor Named MT
Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India CI
UBS Boosts Alcon PT, Affirms Buy Rating MT
ALCON : price target raised by UBS CF
Argus Raises Alcon's Price Target to $100 From $90, Maintains Buy Rating MT
Chart Alcon Inc.
More charts
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows: - ophthalmic surgical products and equipment (56.7%): consumables (51.2% of net sales), implantable products (32%) and other products (16.8%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors; - vision care products (43.3%): contact lenses (59.2% of sales) and eye care products (40.8%; eye drops and ophthalmic ointments, etc.) At the end of 2023, the group operated 19 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (46%), Japan (6.2%), China (5.6%) and other (41,5%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
89.37 USD
Average target price
93.64 USD
Spread / Average Target
+4.78%
Consensus
  1. Stock Market
  2. Equities
  3. ALC Stock
  4. News Alcon Inc.
  5. Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump